131030 — Optus Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩94bn
- KR₩38bn
- KR₩72bn
- 90
- 75
- 33
- 78
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 69,157 | 77,395 | 69,555 | 61,555 | 57,811 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 13,656 | 4,108 | 6,564 | 7,908 | 9,995 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 88,659 | 93,431 | 91,017 | 81,386 | 91,772 |
Net Property, Plant And Equipment | 24,138 | 28,267 | 38,717 | 43,735 | 42,501 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 118,969 | 129,897 | 140,038 | 136,240 | 149,460 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9,715 | 8,582 | 11,375 | 9,760 | 13,072 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 11,222 | 11,014 | 13,018 | 11,773 | 15,009 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 107,747 | 118,883 | 127,021 | 124,467 | 134,451 |
Total Liabilities & Shareholders' Equity | 118,969 | 129,897 | 140,038 | 136,240 | 149,460 |
Total Common Shares Outstanding |